A Phase II Study of OSI-774 (NSC 718781) in Patients With Locally Advanced and/or Metastatic Carcinoma of the Endometrium.
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Erlotinib (Primary)
- Indications Endometrial cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 24 Jan 2014 According to ClinicalTrials.gov,actual end date changed from Jan 2011 to April 2007 .
- 21 Sep 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.